SCHEMBL5449883

SCHEMBL5449883

O=C(NC1CCCCC1)c1ccc2[nH]c3c(c2c1)CCCC3NC1CCCCC1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RB1 P06400 6/20 0.61
RAB9A P51151 2/20 0.56
BRD3 Q15059 3/20 0.52
MAPT P10636 2/20 0.52
ALOX15 P16050 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 1/20 0.48
GLA P06280 1/20 0.48
KMT2A Q03164 1/20 0.48
DHODH Q02127 1/20 0.48
GAA P10253 1/20 0.47
CASP6 P55212 1/20 0.47
TP53 P04637 1/20 0.46
CASP1 P29466 1/20 0.46
NPC1 O15118 1/20 0.46
CDC42 P60953 1/20 0.45
TLR8 Q9NR97 1/20 0.45
TLR7 Q9NYK1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5454070 0.91 RB1 (0.63) RB1BRD3MAPTALOX15SMN1; SMN2
SCHEMBL5459696 0.90 RB1 (0.60) RB1RAB9ABRD3MAPTALOX15
SCHEMBL5455603 0.89 RB1 (0.57) RB1RAB9ABRD3MAPTALOX15
SCHEMBL5467992 0.88 RB1 (0.62) RB1BRD3MAPTALOX15SMN1; SMN2
SCHEMBL5456566 0.88 RB1 (0.56) RB1RAB9ABRD3MAPTALOX15
SCHEMBL5451949 0.88 RB1 (0.56) RB1RAB9ABRD3MAPTALOX15
SCHEMBL5468069 0.87 RB1 (0.55) RB1RAB9ABRD3MAPTALOX15
SCHEMBL5451412 0.86 RB1 (0.56) RB1RAB9ABRD3MAPTALOX15
SCHEMBL5468198 0.86 RB1 (0.53) RB1RAB9ABRD3MAPTALOX15
SCHEMBL5449868 0.86 RB1 (0.60) RB1BRD3MAPTALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 RB1 1821/4885RAB9A 2512/4885BRD3 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.